Search
SOLACI Congress
HomeStructural heart diseaseValvular Aortic valve

Valvular Aortic valve

View Category

Mitral valve

Evolution at 1 Year for the PARTNER 3 Mitral Valve-in-Valve Study

At present, the structural failure of mitral bioprostheses due to their deterioration poses a significant challenge. While...
Dr. Carlos Fava -
Learn More
Mitral valve

Edge-to-Edge Tricuspid Valve Repair 3-Year Follow Up

Tricuspid regurgitation (TR) is associated to fatigue and peripheral edema, and medical treatment with diuretics has a...
Dr. Carlos Fava -
Learn More
Antithrombotic Anticoagulants

Should We Withdraw Anticoagulation Before TAVR?

Approximately one-third of patients undergoing transcatheter aortic valve replacement (TAVR) have atrial fibrillation and are on oral...
Dr. Carlos Fava -
Learn More
Structural heart disease

MATTERHORN: Edge-to-Edge Repair vs. Surgery for Secondary Mitral Valve Regurgitation

Frequently associated with hospitalization for cardiac failure and mortality, secondary mitral valve regurgitation (MR) is the most...
Dr. Carlos Fava -
Learn More
Structural heart disease

RESHAPE-HF2 Trial: Edge-to-Edge Repair in Secondary Mitral Valve Regurgitation vs. Complete Medical Treatment

Severe secondary Mitral Valve Regurgitation (MR) has been associated with increased hospitalization and mortality. Even though optimal...
Dr. Carlos Fava -
Learn More
Coronary disease

¿What Should We Do About Significant Coronary Lesions in TAVR?

Aortic stenosis and coronary artery disease (CAD) share risk factors, which means significant lesions will coexist in...
Dr. Carlos Fava -
Learn More
Structural heart disease

ESC 2024 | RHEIA Trial: Transcatheter vs. Surgical Replacement in Women

The RHEIA trial is the first randomized, women-exclusive international study aimed to assess the safety and efficacy...
Dr. Omar Tupayachi -
Learn More
Antithrombotic Anticoagulants

ESC 2024 | POPular PAUSE TAVI: Continuation vs. Discontinuation of Oral Anticoagulant Therapy During TAVI

Due to their advanced age and comorbidities, many patients with severe aortic stenosis scheduled for transcatheter aortic...
Dr. Omar Tupayachi -
Learn More

SOLACI is the reference organization for Latin American cardiovascular interventionism.

Last News

Secondary Access in TAVI: Is Transradial Approach our Best Bet?

Dr. Omar Tupayachi - 0
In some countries, transcatheter aortic valve implantation (TAVI) has become the treatment of choice for patients with severe symptomatic aortic stenosis. Primary transfemoral access...

FAVOR III Europa Sub-Analysis: Coronary Revascularization Deferral Based On QFR vs FFR

Dr. Andrés Rodríguez - 0
When it comes to intermediate coronary lesion revascularization decision making, functional assessment is the recommended. At present, several indices are used, such as fractional...

ROUTE TRAIL: DKCRUSH vs. DKRUSH Culotte in Non-Left Main Bifurcation Lesions

Dr. Carlos Fava - 0
Coronary bifurcation lesions represent a frequent technical challenge, making between 15% and 20% of cases. Though provisional stenting is mostly used, complex bifurcations are...

Institutional News

Hemodynamics and Interventional Cardioangiology Hybrid Training Course SOLACI-CACI

solaci - 0
We are now open for registration to the hybrid training course on Hemodynamics and Interventional Cardioangiology for Technicians and Nurses SOLACI-CACI 2025 Find all course...

Check out the best images of the El Salvador 2024 Sessions

solaci - 0
Review the highlights of the XLIX SOLACI Regional Sessions held at the Intercontinental Hotel in San Salvador, El Salvador between November 7 and 8,...

The El Salvador 2024 Sessions are coming soon

solaci - 0
The XLIX SOLACI 2024 Regional Sessions (17th Central America & the Caribbean) are approaching, and will take place in the city of San Salvador (El Salvador)....

Access

Adolfo Alsina 2653 · Piso 2H · CABA · Buenos Aires · Argentina · (5411) 4954 7173 · info@solaci.org · solaci.org · Terms of Use -Privacy Policy